Why an Alzheimer's-focused biotech hoping to 'change the world' shed 70% of its value

Why an Alzheimer's-focused biotech hoping to 'change the world' shed 70% of its value
·2 min read

A clinical trial showed that patients with the greatest reduction in a specific bacterium saw the greatest cognitive benefit from the South San Francisco company's drug, but the trail failed to meet its primary targets.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting